Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone973-822-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.83 billion
Profitability
Miscellaneous
Employees10,000
Next Earnings Date2/13/2020 (Confirmed)
OptionableOptionable
Zoetis (NYSE:ZTS) Frequently Asked Questions
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis announced a quarterly dividend on Friday, December 13th. Shareholders of record on Friday, January 17th will be given a dividend of $0.20 per share on Tuesday, March 3rd. This represents a $0.80 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date of this dividend is Thursday, January 16th. This is an increase from Zoetis's previous quarterly dividend of $0.16. View Zoetis' Dividend History.
How will Zoetis' stock buyback program work?
Zoetis declared that its Board of Directors has approved a share repurchase plan on Wednesday, December 12th 2018, which allows the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 4.7% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's leadership believes its shares are undervalued.
How were Zoetis' earnings last quarter?
Zoetis Inc (NYSE:ZTS) issued its quarterly earnings results on Thursday, November, 7th. The company reported $0.94 EPS for the quarter, beating the Zacks' consensus estimate of $0.88 by $0.06. The company earned $1.58 billion during the quarter, compared to analyst estimates of $1.58 billion. Zoetis had a net margin of 23.76% and a return on equity of 70.78%. The company's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.83 earnings per share. View Zoetis' Earnings History.
When is Zoetis' next earnings date?
How can I listen to Zoetis' earnings call?
Zoetis will be holding an earnings conference call on Thursday, February 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Zoetis issued on next quarter's earnings?
Zoetis updated its FY19 earnings guidance on Thursday, November, 7th. The company provided earnings per share guidance of $3.57-3.62 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.57. The company issued revenue guidance of $6.24 billion, compared to the consensus revenue estimate of prior $3.53-3.60.
What price target have analysts set for ZTS?
15 analysts have issued 1 year price targets for Zoetis' stock. Their forecasts range from $105.00 to $145.00. On average, they anticipate Zoetis' share price to reach $129.54 in the next twelve months. This suggests that the stock has a possible downside of 5.0%. View Analyst Price Targets for Zoetis.
What is the consensus analysts' recommendation for Zoetis?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.
Has Zoetis been receiving favorable news coverage?
Press coverage about ZTS stock has trended somewhat negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Zoetis earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Zoetis.
Are investors shorting Zoetis?
Zoetis saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 5,940,000 shares, an increase of 21.0% from the December 31st total of 4,910,000 shares. Based on an average daily volume of 2,070,000 shares, the days-to-cover ratio is presently 2.9 days. Approximately 1.3% of the company's stock are short sold. View Zoetis' Current Options Chain.
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).
What other stocks do shareholders of Zoetis own?
Who are Zoetis' key executives?
Zoetis' management team includes the folowing people:
- Mr. Juan Ramón Alaix, CEO & Director (Age 68)
- Mr. Glenn C. David, Exec. VP & CFO (Age 47)
- Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
- Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
- Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)
Who are Zoetis' major shareholders?
Zoetis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Milestone Resources Group Ltd (0.17%), New York State Teachers Retirement System (0.15%), State of Michigan Retirement System (0.12%), Artemis Investment Management LLP (0.10%), AMI Asset Management Corp (0.09%) and Strs Ohio (0.09%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.
Which major investors are selling Zoetis stock?
ZTS stock was sold by a variety of institutional investors in the last quarter, including Sonora Investment Management LLC, Artemis Investment Management LLP, Stack Financial Management Inc, Strs Ohio, Braun Stacey Associates Inc., Meag Munich Ergo Kapitalanlagegesellschaft MBH, DAVENPORT & Co LLC and AMI Asset Management Corp. Company insiders that have sold Zoetis company stock in the last year include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.
Which major investors are buying Zoetis stock?
ZTS stock was bought by a variety of institutional investors in the last quarter, including Milestone Resources Group Ltd, Johanson Financial Advisors Inc., TIAA FSB, James Investment Research Inc., Windward Capital Management Co. CA, Advisors Capital Management LLC, Chapman Investment Management LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for Zoetis.
How do I buy shares of Zoetis?
Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zoetis' stock price today?
One share of ZTS stock can currently be purchased for approximately $136.31.
How big of a company is Zoetis?
Zoetis has a market capitalization of $64.92 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.
What is Zoetis' official website?
How can I contact Zoetis?
Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]
MarketBeat Community Rating for Zoetis (NYSE ZTS)
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
